Reports Q3 revenue $62.3M, consensus $60.58M. “We had a strong third quarter with solid revenue growth performance and meaningful operational improvement,” said Albert DaCosta, Chairman and Chief Executive Officer. “This has been a monumental year for product introductions and we are excited to see our investments in R&D contributing to top-line growth. Paragon 28 (FNA) is well positioned to continue improving the surgeon experience and foot and ankle patient outcomes.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FNA: